How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Date
2019-08-07Journal
VaccinePublisher
Elsevier Ltd.Type
Article
Metadata
Show full item recordAbstract
Controlled Human Infection Models (CHIMs) now exist for several infectious diseases. CHIMs offer significant insight into disease pathogenesis, as well the potential to rapidly test clinical proof-of-concept of vaccine candidates. The application of CHIMs to identify a correlate of protection that may reduce the sample size of, or obviate the need for clinical efficacy studies to achieve licensure is of considerable interest to vaccine developers and public health stakeholders. This topic was the subject of a workshop at the 2018 Vaccines Against Shigella and ETEC (VASE) conference, in the context of O-antigen-based Shigella vaccines. © 2019 The AuthorsSponsors
This work was supported by the Bill and Melinda Gates Foundation (OPP1135836).Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063930358&origin=inward; http://hdl.handle.net/10713/10145ae974a485f413a2113503eed53cd6c53
10.1016/j.vaccine.2019.03.036